Eli Lilly and Company (NYSE:LLY) – Investment analysts at SunTrust Banks lifted their Q3 2017 earnings estimates for shares of Eli Lilly and in a research note issued on Tuesday. SunTrust Banks analyst J. Boris now forecasts that the company will earn $1.03 per share for the quarter, up from their previous estimate of $1.02. SunTrust Banks also issued estimates for Eli Lilly and’s FY2017 earnings at $4.17 EPS and FY2018 earnings at $4.42 EPS.

LLY has been the subject of a number of other reports. Piper Jaffray Companies restated a “buy” rating and issued a $103.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research note on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating and set a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Berenberg Bank reiterated a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research note on Thursday, July 27th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $92.00 target price on shares of Eli Lilly and in a research note on Tuesday, May 16th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $87.97.

ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/08/suntrust-banks-equities-analysts-raise-earnings-estimates-for-eli-lilly-and-company-lly.html.

Shares of Eli Lilly and (LLY) opened at 81.54 on Friday. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72. The company has a 50-day moving average price of $81.04 and a 200 day moving average price of $82.03. The firm has a market capitalization of $86.02 billion, a price-to-earnings ratio of 35.28 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period in the previous year, the company earned $0.86 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.55%. Eli Lilly and’s dividend payout ratio is presently 90.04%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the transaction, the insider now directly owns 124,265,804 shares of the company’s stock, valued at approximately $10,491,761,831.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the transaction, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold a total of 826,900 shares of company stock valued at $68,610,132 over the last ninety days. Insiders own 0.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Ronna Sue Cohen raised its holdings in Eli Lilly and by 0.4% in the 2nd quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after acquiring an additional 9 shares in the last quarter. Accredited Investors Inc. raised its holdings in Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after acquiring an additional 14 shares in the last quarter. Sunbelt Securities Inc. raised its holdings in Eli Lilly and by 0.5% in the 1st quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after acquiring an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its holdings in Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after acquiring an additional 19 shares in the last quarter. Finally, Pillar Pacific Capital Management LLC raised its holdings in Eli Lilly and by 0.3% in the 1st quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock valued at $595,000 after acquiring an additional 20 shares in the last quarter. 75.77% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.